Diabetes-Resistant NOR Mice Are More Severely Affected by Streptozotocin Compared to the Diabetes-Prone NOD Mice: Correlations with Liver and Kidney GLUT2 Expressions by Kahraman, S. et al.
Diabetes-Resistant NOR Mice Are More
Severely Affected by Streptozotocin
Compared to the Diabetes-Prone
NOD Mice: Correlations with Liver
and Kidney GLUT2 Expressions
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Kahraman, S., C. Aydin, G. O. Elpek, E. Dirice, and A. D. Sanlioglu.
2015. “Diabetes-Resistant NOR Mice Are More Severely Affected
by Streptozotocin Compared to the Diabetes-Prone NOD Mice:
Correlations with Liver and Kidney GLUT2 Expressions.” Journal
of Diabetes Research 2015 (1): 450128. doi:10.1155/2015/450128.
http://dx.doi.org/10.1155/2015/450128.
Published Version doi:10.1155/2015/450128
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:14065543
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Research Article
Diabetes-Resistant NOR Mice Are More Severely Affected by
Streptozotocin Compared to the Diabetes-Prone NOD Mice:
Correlations with Liver and Kidney GLUT2 Expressions
S. Kahraman,1 C. Aydin,2 G. O. Elpek,3 E. Dirice,4 and A. D. Sanlioglu1
1Center for Gene and Cell Therapy, Akdeniz University, 07058 Antalya, Turkey
2Center for Genetic Diagnosis, Akdeniz University, 07058 Antalya, Turkey
3Department of Pathology, Akdeniz University Faculty of Medicine, 07058 Antalya, Turkey
4Section of Islet Cell and Regenerative Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA
Correspondence should be addressed to A. D. Sanlioglu; ahter@akdeniz.edu.tr
Received 6 October 2014; Revised 19 December 2014; Accepted 20 December 2014
Academic Editor: Norman Cameron
Copyright © 2015 S. Kahraman et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nonobese Diabetic (NOD) mice are susceptible strains for Type 1 diabetes development, and Nonobese Diabetes-Resistant (NOR)
mice are defined as suitable controls for NOD mice in non-MHC-related research. Diabetes is often accelerated in NOD mice
via Streptozotocin (STZ). STZ is taken inside cells via GLUT2 transmembrane carrier proteins, the major glucose transporter
isoforms in pancreatic beta cells, liver, kidneys, and the small intestine.We observed severe adverse effects inNORmice treatedwith
STZ compared to NOD mice that were made diabetic with a similar dose. We suggested that the underlying mechanism could be
differential GLUT2 expressions in pancreatic beta cells, yet immunofluorescent and immunohistochemical studies revealed similar
GLUT2 expression levels. We also detected GLUT2 expression profiles in NOD and NOR hepatic and renal tissues by western
blot analysis and observed considerably higher GLUT2 expression levels in liver and kidney tissues of NOR mice. Although beta
cell GLUT2 expression levels are frequently evaluated as a marker predicting STZ sensitivity in animal models, we report here
very different diabetic responses to STZ in two different animal strains, in spite of similar initial GLUT2 expressions in beta cells.
Furthermore, use of NOR mice in STZ-mediated experimental diabetes settings should be considered accordingly.
1. Introduction
Nonobese Diabetic (NOD) mice are the most frequently
preferred animal models in research related to type 1 diabetes
(T1D) and other autoimmune conditions [1, 2]. Selection of
appropriate controls for NOD mice depends on the type and
aim of research. Nonobese Diabetes-Resistant (NOR) mice
are defined by the producer Jackson Lab as suitable control
strains for NODmice in non-MHC-related studies. NOR/LtJ
mice produced by Jackson Lab are thought to have originated
from the NOD/LtJ strain through a genetic contamination
with C57BLKS/J, where limited regions of the NOD/LtJ
genome have been replaced by genome from the C57BLKS/J
strain. While sharing the same MHC as NOD mice, NOR
mice display a stronger T cell function compared to NOD
mice, and islet inflammation in these mice does not progress
beyond peri-insulitis [3, 4].
Spontaneous diabetes development takes approximately
30 weeks in NOD mice with a requirement for pathogen-
free conditions. Thus, development of diabetes is frequently
accelerated in NOD mice via agents such as Streptozotocin
(STZ) and Cyclophosphamide (CY). While CY exerts its
primary effect on CD4+CD25+ Treg cells [5], STZ is internal-
ized through GLUT2 glucose transporters which are located
exclusively on beta cells in the pancreatic setting, and also in
liver, kidney, and small intestine cells. Accordingly, GLUT2
knockout mice are not susceptible to STZ [6]. STZ is an
antibiotic produced by Streptomyces achromogenes and is also
used as an FDA-approved drug in the metastatic cancer
of pancreatic islets cells. It inhibits glucose oxidation and
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glucose-induced insulin secretion in beta cells via nitric
oxide production, alkylation, and DNA fragmentation [7–
10]. DNA fragmentation is followed by poly(ADP-ribose)
activation and a sustained reduction in cellular NAD+ levels
that induces cell death [6]. STZ can directlymethylate nuclear
and mitochondrial DNA and increases FasL expression.
Glucose transporter 2 (GLUT2) is a transmembrane car-
rier proteinwhich provides passive glucose transport through
the cell membrane. While being a member of facilitative
glucose transporters family which uptake and release glucose
and other certain sugars, GLUT2 is unique in accepting
fructose as a substrate and also in its ability to act as a
glucose sensor [11].Thus, it plays an important role in glucose
homeostasis, functioning as a part of the glucose sensory
mechanism in pancreatic beta cells [12]. GLUT2 is expressed
primarily in pancreatic beta cells and liver cells, as well as in
absorptive epithelial cells such as the basolateral membrane
of the kidney proximal tubules, and the small intestine [13].
GLUT2 is known to act as the main glucose transporter
and sensor in rodent islets. Although claimed not to be the
primary glucose transporter in human beta cells, SNPs in
GLUT2 gene was found to predict conversion to diabetes
from impaired glucose tolerance [14–16].
GLUT2 expression levels in pancreatic beta cells are
defined as a marker for degree of susceptibility to STZ in
various animal models. For instance, Old World Monkeys
have lower levels of GLUT2 expression in beta cells, which is
reflected as resistance to STZ. On the other hand, NewWorld
Monkeys with higher GLUT2 expression in pancreatic beta
cells are fairly susceptible to the diabetogenic effects of STZ
[17]. STZ leads to kidney and liver toxicity as well as beta cell
damage [18].
In a previous study by our group, where we accelerated
T1D in NOD mice by STZ and CY applications, NOR mice
were put through similar applications as a control strain
[19]. However, NOR mice displayed a considerably higher
sensitivity against STZ compared to the NODmice.While no
unexpected deaths were observed in NOD mice during the
14-day follow-up after STZ application, sudden deaths were
evident in NOR mice starting from day six. CY, which exerts
its diabetogenic effect through regulator T cell suppression,
did not have any diabetic/toxic effects on NOR mice. We
hypothesized that the strong effect of STZ in thesemice could
be due to a species-specific difference, most likely related
with high GLUT2 receptor expression in pancreatic beta
cells. Thus we investigated in situGLUT2 expression levels in
pancreatic tissues of NOD and NOR mice prior to and fol-
lowing STZ application, while evaluating pancreatic islet
compositions in these mice through various stages of disease.
In addition, GLUT2 expression levels in liver and kidney
tissues of the two strains were compared by western blot
protein analysis.
2. Materials and Methods
2.1. Animal Tissues. Animal tissues used in this study (par-
affin-embedded pancreata and frozen liver and kidneys)
belong to female NOD and NOR mice that were purchased
from the Jackson Laboratory, USA, for an earlier study [19].
All animals had received a single dose of 150mg/kg STZ at 10
weeks of age.
2.2. Ethics Statement. All animal works in the previous
study [19], which provided the frozen and paraffin-embedded
materials for the present study, were conducted under the
approval of the Institutional Animal Care and Use Ethics
Committee of Akdeniz University (Permit number 07-09/01)
and in accordance with the Helsinki Declaration guidelines.
Applied procedures included STZ injections, anesthesia, and
tissue extractions.
2.3. Immunofluorescence Stainings and Analysis. For immun-
ofluorescence staining, slides were first kept at 60∘C for two
hours. After xylol and alcohol series, heat-mediated anti-
gen retrieval was performed in 10mM sodium citrate buffer
(pH 6.0). Donkey serum (5%) was applied for 1 hour at
room temperature (RT) to prevent nonspecific stainings.
Overnight incubation at 4∘C by primary antibodies was done
in following dilutions: guinea pig anti-insulin at 1/100 dilu-
tion (Abcam, ab7842), rabbit anti-glucagon at 1/50 dilution
(Abcam, ab18461), and goat anti-GLUT2 at 1/50 dilution
(Abcam, ab111117). Next day after PBS wash series, secondary
antibodies were applied for 1 hour at RT at 1/200 dilution:
antiguinea pig CY2 (Jackson Immunoresearch, 706-226-
148), anti-rabbit Texas Red (Santa Cruz, sc-2784), and anti-
goat Texas Red (Abcam, ab7123). PBS wash series were
then followed by application of DAPI-containing mounting
medium.
ImageJ analysis program was used for quantitative anal-
ysis of stainings. For GLUT2 stainings, GLUT2 fluorescence
rate was normalized to the surface area of the insulin-positive
cells. Colored pictures taken from dual-stained islets were
converted into gray-toned images. Insulin-stained areas were
defined in individual islets, and the corresponding surface
areas were calculated. These defined areas were then merged
on the GLUT2-stained areas, and the fluorescence intensities
were determined. Dividing the measured fluorescence inten-
sities into surface area values of the insulin-stained cells gave
us the “mean fluorescence intensities” [20]. Three different
pancreata and 5 to 25 islets from each of the pancreata were
analysed.
2.4. Identification of Alpha and Beta Cell Ratios. Alpha and
beta cell ratios were determined by counting insulin and
glucagon-stained cells in islets following dual immunofluo-
rescence stainings. Three different pancreata were examined
to reach average values in each study group, with 5 to 25 islets
evaluated in each pancreas.
2.5. Immunohistochemical Stainings and Analysis. Sections of
5 𝜇mthickness were deparaffinized through xylol and alcohol
series. Heat-mediated antigen retrieval application in 10mM
sodium citrate buffer (pH 6.0) was followed by quenching of
endogenous peroxidase activity through hydrogen peroxide
block treatment for 30 minutes at RT. Ultra V blocking was
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Figure 1: Changes in pancreatic islet content following STZ treatment. Representative images showing pancreatic islet contents in NOD
(upper panel) and NOR mice (lower panel) before and after STZ application. Pancreatic tissues were stained with anti-insulin (green) and
anti-glucagon (red) antibodies, and counterstaining was done with DAPI nuclear stain. Pictures represent islet images of pancreatic tissues
isolated from animals sacrificed on day 0 (before STZ injection) and on days 1, 2, 4, 7, 11, and 14, after 150mg/kg STZ injection (𝑛 = 3 for each
time point).
performed for 5 minutes at RT for inhibition of nonspe-
cific stainings. After removal of blocking solution, sections
were incubated with rabbit-derived primary antibody against
GLUT2 receptor at 4∘C overnight, at a 1/50 antibody dilution
(Abcam, ab104622). Next day, tissues were washed in PBS
series and kept in HRP-conjugated anti-rabbit secondary
antibody (Abcam, ab6721), at a 1/200 dilution, for 1 hour at
RT. PBS wash series were followed by DAB chromogen incu-
bation for 1min. After 20 seconds of hematoxylin staining of
the cell nuclei, alcohol and xylol series were applied. Slides
were mounted with Entellan (Merck, 7961).
The stained slides were blind-evaluated by a pathologist
(GOE) who had no prior knowledge on tissue origins. The
scoring system is based on both intensity and distribution
(percentage of the positively stained cells) of GLUT2 stain-
ings. Positive cells counted at 400x magnification were eval-
uated relative to the total number of cells. Intensity of stain-
ings was classified as (0) negative; (1) weak; (2) moderate; and
(3) strong. Marker distribution was scored as (0) less than
10%, (1) between 10% and 40%, (2) between 40% and 70%,
and (3) for more than 70% of the cells stained positive. The
sum of the intensity and marker distribution scores gave the
final staining score.
2.6. Western Blotting. Frozen kidneys and livers from NOD
and NOR mice were homogenized in lysis buffer (pH 7.4)
containing 100mM NaF, 50mM Hepes, 150mM NaCl,
10% Glycerol, 1.2% Triton X, 1mM MgCl
2
, 1 mM EDTA,
1mM Na
3
VO
4
, and protease inhibitor cocktail (Roche,
11836145001). Total protein concentration was determined by
Bradford Protein Assay (Bio-Rad). Lysates (50𝜇g protein)
were run in 8% SDS-PAGE and transferred to PVDF mem-
brane (Millipore). Membranes were blocked for 10 minutes
at room temperature with 5% milk and were incubated
overnight at 4∘C with antibodies against GLUT2 (1 : 1,000,
sc-9117; Santa Cruz Biotechnology) or 𝛽-actin (1 : 1,000, sc-
81178; Santa Cruz Biotechnology). After three washing series
(10 minutes), the membranes were incubated for 1 hour at
RT with antibodies against rabbit IgG-HRP conjugate (1;
2000, #170-6515, Bio-Rad) or mouse IgG-HRP conjugate (1;
2000, #170-6516, Bio-Rad). After three 10-minute washes,
signals were visualized via ECL (Roche) and quantified using
ImageQuant version 5.1 software.
2.7. Statistical Analysis. Immunohistochemistry results were
statistically analysed by Prism GraphPad software (version
5.0a.128). Normality tests were carried out by Shapiro-Wilk
method, andMann-Whitney𝑈 test was used for comparisons
of the scores between two independent groups. Statistics for
the immunofluorescent results were done via Student’s 𝑡-test.
Statistical significance was considered at 5% probability level
(𝑃 < 0.05).
3. Results
3.1. Structural Alterations in the Pancreatic Islets and Quan-
titative Changes in the Islet Cell Contents of NOD and NOR
Mice following STZ Application. Following a single dose of
150mg/kg STZ injection, the pancreatic islet morphology
changed gradually in both NOD and NOR mice during
the 14 days of follow-up. Beta cell numbers decreased in
both strains, with a faster rate in NOR mice (Figure 1). We
observed that NORmice had nearly half the beta cell content
compared to that of NOD mice at day 2 and less number
of beta cells at all points after that. Proportion of alpha
cells increased gradually in both strains. Alpha and beta cell
percentages in each test point are shown in Figure 2.
3.2. Expression Levels of GLUT2 in NOD and NOR Pancreatic
Islets before and after STZ Application. Pancreatic islets of
NOD and NOR mice were dually stained for insulin and
GLUT2 expressions prior to and following STZ injection,
and immunofluorescence intensities were analysed. Similar
GLUT2 expression levels were evident in both mice strains
at day 0 (Figure 3). Differences in islet GLUT2 expressions
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Figure 2: Quantitative analysis of alpha and beta cell contents in pancreatic islets of NOD and NOR mice following STZ injection. Upper
panel displays changes in beta (a) and alpha (b) cell percentages within the islets compared in NOD (lighter bars) and NOR mice (darker
bars). In the lower panel, progressive alterations in comparative proportions of alpha and beta cell contents are shown in NOD (c) and in
NOR mice (d). ∗𝑃 < 0.05, NOD versus NOR (Student’s 𝑡-test). Error bars represent ± SEM (𝑛 = 3 for each time point).
betweenNODandNORmice following STZ applicationwere
comparatively analysed. Furthermore, progressive changes
in islet GLUT2 expression levels after STZ injection were
evaluated separately in each of the mice in comparison to
the day 0 values of the corresponding strain. According
to our results, GLUT2 levels did not change significantly
in islets of NOD mice throughout the 14-day follow-up,
while it was elevated in NOR mice starting from day 4
of injection. GLUT 2 expression levels in NOR mice islets
were significantly higher compared to NODs, between days
4 and 14. GLUT2 expressions were maintained significantly
higher in NOR mice after STZ injection, in comparison to
day 0 values (Figure 3(b)). Immunohistochemical stainings
revealed similar results (Figure 4).
3.3. GLUT2 Expression Levels in Livers and Kidneys of NOD
and NOR Mice Prior to STZ Application. Lysates obtained
from frozen kidneys and livers of the non-STZ treated NOD
and NOR mice (day 0 tissues) were used for western blot
analysis of GLUT2 expressions (Figure 5). Scarce levels of
GLUT2 were detected in the livers of 10-week-old, non-STZ
treated female NOD mice. The sex- and age-matched NOR
mice, on the other hand, displayed higher levels of GLUT2
in liver. This result was confirmed by immunohistochemical
stainings on the same tissues following paraffin embedding
(Figure 5). GLUT2 levels in the kidneys of the non-STZ
treated NOR mice were substantially higher compared to
the NODs. Immunohistochemical stainings revealed similar
results.
4. Discussion
Streptozotocin (STZ) is a glucose analogue frequently used
as a diabetic agent in various animal models. We previously
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Figure 3: GLUT2 expression levels in the pancreatic beta cells of NOD and NORmice. (a) Representative images of dual stainings for insulin
(red) and GLUT2 expressions (green) in the presence of DAPI counter-staining (blue), before STZ application (day 0). (b) Mean fluorescence
intensities for GLUT2 expression in NOD (lighter bars) and NOR islet beta cells (darker bars) on days 0, 1, 2, 4, 7, 11, and 14 of STZ injection.
Five to twenty islets per animal were analysed via ImageJ program (𝑛 = 3/group). ∗𝑃 < 0.05, significance between values observed in NOD
versus NOR mice; §𝑃 < 0.05, significance between values detected in NOR mice before STZ injection and at different time points after
treatment (Student’s 𝑡-test).
observed strong adverse effects caused by 150mg/kg STZ
injection in 10-week-old femaleNonobeseDiabetes-Resistant
(NOR) mice that were intended to be used as age- and
sex-matched controls for Nonobese Diabetic (NOD) mice
[19]. To investigate the underlying mechanism, we examined
pancreas, liver, and kidney tissues of the animals for possible
differences in GLUT2 expression levels between the twomice
strains.
As expected, STZ injection triggered a decrease in pan-
creatic beta cell count, in both NOD and NOR mice [21, 22].
Interestingly, NOR mice displayed a faster decrease in beta
cell numbers and a wider difference between the alpha and
beta cell percentages within the islets, at most time points
chosen for analysis (Figure 2). Yet in spite of fast reductions
in beta cell numbers, GLUT2 expression levels significantly
increased gradually in the islets of NORmice, unlike those of
theNODmice (Figure 3). Higher blood sugar levels were also
evident in thesemice in periodicmeasurements, compared to
the NODmice [19]. As GLUT2 expression is confined to beta
cells in the islet setting, higher blood sugar concentrations
due to STZ-induced beta cell failure is likely to be the mech-
anism responsible from the rise in GLUT2 expression levels.
Glucose-stimulated upregulation of GLUT2 expression was
shown in hepatocytes via direct effect on gene transcription
and in rat proximal tubule brush border membrane [13, 23,
24]. In contrast, islets prepared from C57BL/6 male mice
treated with multiple low doses of STZ displayed decreased
GLUT2 expression levels [25]. Multiple low doses of STZ are
6 Journal of Diabetes Research
Day 0 Day 4
N
O
D
N
O
R
Day 7 Control
100𝜇m
Figure 4: GLUT2 immunohistochemistry stainings in NOD and NOR islets. Representative islet images are shown demonstrating GLUT2
expression levels prior to (day 0) and after STZ application (days 4 and 7). Hematoxylin counterstainingwas performed following anti-GLUT2
antibody application. Tissues depicted as “control” were treated with secondary antibody only.
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Figure 5:Western blot analysis and immunohistochemical stainings of GLUT2 expressions in the livers and kidneys of non-STZ treatedNOD
and NOR mice. Representative images are shown demonstrating GLUT2 expression levels in livers (upper panel) and kidneys (lower panel)
of NOD and NOR mice via western blot (left) and immunohistochemical stainings (right), prior to STZ application (day 0). Hematoxylin
counterstaining was performed following anti-GLUT2 antibody application. Immunohistochemistry images show the corresponding tissues
at 10x magnification on the left side, and at 40x magnification in the middle depictions. Arrows are placed for comparison of the staining
intensities. Control tissues, treated with secondary antibody only, are shown at right.
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related to induction of autoimmune diabetes. We applied a
single high dose of STZ to both NOD and NOR mice, which
rather caused quick and sharp rises in blood sugar levels
apparently due to more immediate beta cell destruction, thus
to immediate high blood sugar levels and presumably the
increased GLUT2 expression levels. It is also noteworthy
that we observed no rise in GLUT2 expression levels in the
pancreatic beta cells of the T1D-prone NOD mice, while
GLUT2 levels were significantly raised in the pancreatic beta
cells of the T1D resistant NOR mice.
In general, NOR mice had higher blood sugar levels and
were affectedmore adversely from STZ application compared
to the NODs.Thismay reflect a somewhat higher exposure of
NOR mice to STZ. We suggested that a possible explanation
might involve higher GLUT2 expression levels in the islets
of NOR mice before STZ application. However, we found
no significant differences in islet GLUT2 expression levels
measured prior to STZ injection in NOD and NOR mice
(Figure 3).
STZ is also known to affect liver and kidney tissues
at varying degrees in different species. This effect is in
accordancewith localization ofGLUT2 receptors primarily in
pancreatic beta cells and hepatocytes, as well as in epithelial
cells of the kidney [13]. As well known, kidneys reabsorb all
the filtered glucose and thus play an important role in glu-
cose homeostasis, to ensure sufficient energy for the fasting
conditions.This mechanism is known to be destructed in the
diabetic setting because hyperglycemia increases the expres-
sion and activity of GLUT2 receptors in the kidney proximal
tubules [26]. STZ-mediated diabetes induction interferes
with glucose transport in kidneys as well [27]. Furthermore,
STZ-induced diabetes in rats is known to produce alter-
ations in structures of hepatocytes and the hepatic functions,
accompanied by impairment in glucose utilization in STZ-
induced diabetes [28]. STZ induction in HepG2 liver cells led
to an increase in oxidative stress markers, caused mitochon-
drial respiratory dysfunction, and resulted in limited induc-
tion of mitochondrial apoptotic pathways [29]. Increase in
GLUT2 expression levels in a glucose concentration manner
was reported in primary rat hepatocytes and hepatocyte cell
lines [24, 30]. Thus higher GLUT2 expression levels in the
liver and kidney tissues of the NORmice compared to NODs
before STZ application suggested higher initial exposures to
STZ in these tissues and thus higher toxicity.
Differing degrees of GLUT2 expression levels in pancre-
atic, hepatic, and renal tissues, as well as between different
species, appear to determine the intensity of the harm caused
by STZ application at a given dose. For instance, common
marmosets were reported as fairly resistant to any rise in
blood sugar levels following STZ application due to low
GLUT2 expression levels in pancreatic islets [17]. Further-
more, the toxic effects of STZ on livers and kidneys of com-
mon marmosets were reported to outweigh its diabetogenic
effects. We observed that liver and kidney tissues of NOR
mice displayed higher GLUT2 levels prior to STZ application,
compared to the NOD mice (Figure 5). Although we do not
have specific values to demonstrate the degree of hepatic and
renal toxicity in the mice strains used in our study, NOR
mice were in very poor health starting from day 4 of STZ
application, with observable fatigue and lack of motion, most
likely due to very high blood sugar levels (measured over
600mg/dL).
In consequence, our results reveal more adverse effects in
the diabetes-resistant NOR mice in response to injection of
a single dose of (150mg/kg) STZ, compared to the diabetes-
prone NOD mice which received the same treatment. Yet
we could not correlate this adverse reaction with differ-
ential GLUT2 levels in pancreatic islets of the two strains
as would be expected. Instead, more severe diabetogenic
effects caused by STZ in NOR mice compared to NODs are
revealed by extremely high blood glucose levels throughout
the follow-up, correlated with higher GLUT2 levels in liver
and kidney tissues. As well known, STZ is a frequently used
experimental diabetes-inducing agent in animal models, as
well as an FDA-approved chemotherapeutic drug. Besides
revealing that NOR mice should be carefully considered for
studies involving relatively high doses of STZ, our results also
refer to the significance of individual differences in GLUT2
expression levels in hepatic and renal tissues as determinants
of STZ toxicity levels.
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